Zymeworks Future Growth

Future criteria checks 0/6

Zymeworks's earnings are forecast to decline at 6% per annum while its annual revenue is expected to grow at 8.2% per year. EPS is expected to grow by 0.6% per annum. Return on equity is forecast to be -45.2% in 3 years.

Key information

-6.0%

Earnings growth rate

0.6%

EPS growth rate

Biotechs earnings growth28.4%
Revenue growth rate8.2%
Future return on equity-45.2%
Analyst coverage

Good

Last updated25 Sep 2024

Recent future growth updates

Recent updates

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 27
Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Earnings and Revenue Growth Forecasts

NasdaqGS:ZYME - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026139-75-86-666
12/31/2025120-81-124-887
12/31/2024109-78-63-297
6/30/202463-113-96-91N/A
3/31/202450-126-77-73N/A
12/31/202376-119-122-118N/A
9/30/2023462205192195N/A
6/30/2023448186159165N/A
3/31/2023446173108116N/A
12/31/2022412124131144N/A
9/30/202230-224-252-234N/A
6/30/202232-237-231-212N/A
3/31/202228-240-224-207N/A
12/31/202127-212-206-192N/A
9/30/202122-211-199-190N/A
6/30/202121-223-161-155N/A
3/31/202131-194-161-155N/A
12/31/202039-181-158-151N/A
9/30/202025-215-147-140N/A
6/30/202030-173-150-135N/A
3/31/202026-163-113-98N/A
12/31/201930-145-96-82N/A
9/30/201957-64-75N/A
6/30/201951-52-23N/A
3/31/201965-291720N/A
12/31/201853-372124N/A
9/30/201874-131013N/A
6/30/201872-111214N/A
3/31/201852-16N/A-5N/A
12/31/201752-11N/A0N/A
9/30/20174-55N/A-47N/A
6/30/20176-51N/A-50N/A
3/31/201711-47N/A-41N/A
12/31/201611-34N/A-35N/A
9/30/201610-30N/A-32N/A
12/31/201510-19N/A-22N/A
12/31/20142-13N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZYME's revenue (8.2% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: ZYME's revenue (8.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZYME is forecast to be unprofitable in 3 years.


Discover growth companies